Financial health
- The company holds more cash ($91M) than total debt ($29M).
- Operating income covered interest expense -65.4× in the latest year.
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$212M | — | — | -28.7% | -26.3% | -$181M | $29M | $91M |
| 2024 | — | -$109M | — | — | -24.7% | -22.0% | -$94M | $28M | $192M |
| 2023 | — | -$76M | — | — | -22.1% | -20.8% | -$74M | $0 | $360M |
| 2022 | — | -$47M | — | — | -26.5% | -23.4% | -$42M | — | $195M |
| 2021 | — | -$36M | — | — | 56.0% | -38.9% | -$28M | — | $88M |
| 2020 | — | -$41M | — | — | 141.8% | -490.9% | -$33M | $14M | $5M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$60M | — | — | -9.2% | -8.1% | -$44M | $59M | $99M |
| Mar '26 | — | -$64M | — | — | -9.2% | -8.5% | -$62M | $29M | $89M |
| Dec '25 | — | -$61M | — | — | -8.2% | -7.5% | -$43M | $29M | $91M |
| Sep '25 | — | -$62M | — | — | -10.9% | -9.9% | -$48M | $29M | $141M |
| Jun '25 | — | -$55M | — | — | -9.0% | -8.3% | -$48M | $29M | $127M |
| Mar '25 | — | -$34M | — | — | -5.2% | -4.8% | -$42M | $29M | $123M |
| Dec '24 | — | -$29M | — | — | -6.6% | -5.9% | -$28M | $28M | $192M |
| Sep '24 | — | -$27M | — | — | -5.7% | -5.4% | -$17M | — | $193M |
| Jun '24 | — | -$26M | — | — | -5.4% | -5.2% | -$15M | — | $281M |
| Mar '24 | — | -$27M | — | — | -8.0% | -7.6% | -$34M | — | $343M |
| Dec '23 | — | -$24M | — | — | -6.8% | -6.4% | -$18M | $0 | $360M |
| Sep '23 | — | -$14M | — | — | -3.9% | -3.8% | -$8M | — | $371M |
| Jun '23 | — | -$16M | — | — | -4.3% | -4.2% | -$13M | — | $378M |
| Mar '23 | — | -$23M | — | — | -9.8% | -9.3% | -$35M | — | $236M |
| Dec '22 | — | -$11M | — | — | -6.4% | -5.6% | -$10M | — | $195M |
| Sep '22 | — | -$16M | — | — | 16.4% | -15.2% | -$10M | — | $102M |
| Jun '22 | — | -$10M | — | — | 11.6% | -8.5% | -$9M | — | $109M |
| Mar '22 | — | -$10M | — | — | 13.4% | -7.9% | -$14M | — | $119M |
| Dec '21 | — | $18M | — | — | -28.2% | 19.6% | $19M | — | $88M |
| Sep '21 | — | -$19M | — | — | -13.2% | -11.9% | — | — | $150M |
See the revenue and net-income charts above for Disc Medicine, Inc.'s multi-year trend.
As of FY2025, Disc Medicine, Inc. reported $29M of total debt against $91M of cash; operating income covered interest expense -65.4×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.